Carisma Therapeutics (NASDAQ:CARM) Upgraded to Strong-Buy at EF Hutton Acquisition Co. I

Carisma Therapeutics (NASDAQ:CARM) was upgraded by analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a research note issued to investors on Wednesday, Zacks.com reports.

Carisma Therapeutics Stock Down 2.7 %

CARM opened at $0.97 on Wednesday. The firm’s 50-day simple moving average is $1.00 and its 200-day simple moving average is $1.19. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.25 and a current ratio of 3.25. Carisma Therapeutics has a twelve month low of $0.80 and a twelve month high of $3.42. The firm has a market cap of $40.44 million, a price-to-earnings ratio of -0.55 and a beta of 1.49.

Carisma Therapeutics (NASDAQ:CARM) last posted its earnings results on Thursday, August 8th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.09. Carisma Therapeutics had a negative net margin of 350.08% and a negative return on equity of 344.89%. The business had revenue of $9.20 million for the quarter, compared to analyst estimates of $3.65 million. Equities research analysts anticipate that Carisma Therapeutics will post -1.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Carisma Therapeutics

A hedge fund recently bought a new stake in Carisma Therapeutics stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 26,006 shares of the company’s stock, valued at approximately $40,000. Point72 Asia Singapore Pte. Ltd. owned about 0.06% of Carisma Therapeutics as of its most recent SEC filing. 44.27% of the stock is owned by institutional investors and hedge funds.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.